Start Date
July 31, 2010
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2010
BMS-824393
Capsule, Oral, 10 mg, once daily
BMS-824393
Capsule, Oral, 30 mg, once daily
BMS-824393
Capsule, Oral, 100 mg, once daily
Placebo
Capsule, Oral, 0 mg, once daily
Peginterferon Alpha-2a
Syringe, subcutaneous 180 mcg/0.5 mL, weekly
Ribavirin
Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
Local Institution, Philadelphia
Washington Hospital Center, Washington D.C.
Maryland Digestive Disease Research, Laurel
Liver Institute Of Virginia Bon Secours Health System, Newport News
Gastrointestinal Specialists Of Georgia Pc, Mareitta
Orlando Immunology Center, Orlando
Vita Medical Center & Research Solutions, Inc., Tamarac
Bach And Godofsky Infectious Diseases, Bradenton
Baylor University Medical Center, Dallas
Research And Education, Inc., San Diego
Local Institution, Coronado
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY